甲福明作为抗病毒疗法可以保护高血糖和糖尿病患者
Xi Wang1,2, Xiaojie Zheng2, Honghan Ge2,3
1School of Public Health, Anhui Medical University, Hefei, Anhui, China.
mBio
|May 20, 2025
概括
过高血糖和糖尿病增加了严重发烧与血栓塞维症综合征病毒 (SFTSV) 感染的死亡风险. 甲胺在减少这些患者的SFTSV复制和死亡率方面表现有前途.
科学领域:
- 病毒学 病毒学
- 代谢障碍 代谢障碍 代谢障碍
- 免疫学 免疫学 免疫学
背景情况:
- 病毒感染可以破坏葡萄糖代谢,但它们对高度致病性病毒的预后的影响尚不清楚.
- 严重发烧与血小板缺血综合征病毒 (SFTSV) 是一种新兴的,高度致病的布尼亚病毒,与高死亡率和像高血糖症这样的代谢障碍有关.
- 降血糖治疗药物的抗病毒机制需要进一步研究.
研究的目的:
- 调查高血糖和糖尿病作为SFTSV感染死亡风险因素的作用.
- 阐明SFTSV感染对葡萄糖代谢的影响,并确定潜在的机制.
- 评估降血糖治疗药物的潜力,特别是甲福林,作为对抗SFTSV的抗病毒策略.
主要方法:
- 多中心临床研究分析了感染SFTSV的患者.
- 实验室和动物研究,以调查SFTSV复制和甲胺的影响.
- 对AMPK-mTOR和IFN-I信号通路的分析.
主要成果:
- 超血糖和先前存在的糖尿病被确定为SFTSV患者死亡的独立风险因素.
- SFTSV感染通过触发葡萄糖生成,抑制AMPK活性和抑制干扰素I (IFN-I) 反应来促进病毒复制.
- 甲福明通过AMPK-mTOR途径抑制自,抑制SFTSV复制,减少感染小鼠和患有高血糖症或糖尿病的患者的病毒性和死亡率.
结论:
- SFTSV感染与葡萄糖代谢障碍相互作用,高血糖和糖尿病恶化了患者的结果.
- 甲胺通过调节自和宿主免疫反应,对SFTSV表现出显著的抗病毒活性.
- 甲胺是治疗SFTSV感染的有前途的治疗药物,特别是在患有潜在葡萄糖代谢障碍的患者中.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
01:06Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:15Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
01:15Hypoglycemia and Glucagon
217
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
217